Beckman Coulter Life Sciences and Pillar Biosciences announce NGS collaboration

Beckman Coulter Life Sciences has announced a collaboration agreement with Pillar Biosciences, which develops and distributes IVD and retrospective use (RUO) NGS testing solutions based on its proprietary SLIMamp technology, to help localise patient testing and optimise the selection of precision therapies for cancer patients.

Pillar Biosciences will develop a series of applications for use on the Biomek NGeniuS Next Generation Library Preparation System (pictured) as part of the agreement. Launched in June of 2022, the Biomek NGeniuS System continues to gain a solid following in research thanks to its open-chemistry concept, user-friendly software, and Dynamic DeckOptix System which reduces errors by identifying misplaced labware.

The application development partnership is initially focused on five commercially available, solid tumour liquid biopsy and haematology panels from Pillar Biosciences: 

  • oncoRevealTM Myeloid
  • oncoRevealTM Solid Tumor v2
  • oncoRevealTM Multi-Cancer plus CNV
  • oncoRevealTM Solid Tumor 22 Gene
  • oncoRevealTM Core LBx.

“Enabling customers to achieve pioneering research breakthroughs is paramount to what we do each and every day at Beckman Coulter Life Sciences,” said Ewan Grant, Senior Director of Liquid Handling and Genomics Product Management. “We are elated that Pillar Biosciences has put their trust in us to deliver a minimal hands-on time solution that removes the burden of slow and gruelling manual library preparation, and we look forward to what will be achieved to further accelerate answers in cancer research.”

“The complexity and costs associated with NGS testing are still barriers to broader adoption. A key advantage for Pillar Biosciences is our streamlined single tube, one-day NGS workflow,” said Randy Pritchard, CEO of Pillar Biosciences. “Combining the simplicity of our NGS library preparation technology with the automation capabilities of the Biomek NGeniuS System will significantly reduce error, assay costs, and hands-on time, helping ensure more oncology researchers get the results they need faster, with lower costs and greater efficiency.”

The application from Pillar Biosciences specifically designed for the Biomek NGeniuS System will be available to customers via a first-of-its-kind electronic application library.

With the global NGS market projected to grow to nearly $27 billion by 2027 (Forecast from Markets and Markets, January 2023), demand is expected to increase for solutions to provide critical assistance to NGS laboratories. The Biomek NGeniuS System provides users flexibility with exclusive software that allows any batch size, from 4 to 24 samples, to be set up from anywhere and monitored remotely. The workstation also reduces loading errors by combining sophisticated optical analytics technology to give users real-time feedback on labware placement.

For more information on the Biomek NGeniuS System, please visit - https://www.beckman.com/landing/genomics/biomek-ngenius.


Latest Issues

The Power to Disrupt - Clinical Diagnostics Expo UK

15 Hatfields
16 September, 2024

Microbe Conference 2024

Crowne Plaza Hotel, Sheffield, UK
20-22 September, 2024

Cardiac Marker Dialogues: Cardiac Biomarkers in Real Time – Experiences and Opportunities

Hilton Glasgow, 1 William Street, Glasgow, Scotland, G3 8HT
26-27 September, 2024

UK NEQAS: Navigating Quality Standards in Point of Care Testing

The Hyatt Regency Hotel, Birmingham, UK
23 October, 2024